> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# aTyr Pharma Orphan Status for Muscular Dystrophy Drug
- URL: https://www.fdaweb.com/atyr-pharma-orphan-status-for-muscular-dystrophy-drug/
- Published: 2017-03-03T12:00:00.000Z
- Updated: 2026-09-14T22:09:51.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138117

FDA has granted aTyr Pharma an orphan drug designation for Resolaris for treating limb girdle muscular dystrophy (LGMD) patients. The company is developing Resolaris as a potential first-in-class intravenous protein therapeutic for treating rare myopathies with an immune component. It says Resolaris is derived from a naturally occurring protein released by human skeletal muscle cells. LGMD refers to a group of rare genetic myopathies, of which there are more than 20 different subtypes, none with approved therapies. It affects about 16,000 patients in the U.S.